uniQure reports mixed Phase I/IIa results for AMT-260 epilepsy gene therapy

Filed June 22, 2026 · Period ending June 19, 2026 · ~1 min read

Key Changes

• high

  Three of six patients in the low-dose cohort achieved 79-100% seizure reductions during months 4-6, while the other three had variable outcomes ranging from a 33% decrease to a 36% increase versus baseline.

  Item 8.01 — Other Events verify on EDGAR →
• high

  No serious adverse events related to AMT-260 or the surgical procedure were reported; all adverse events were mild or moderate, with headache most common (2 patients), and no immunosuppression was required.

  Item 8.01 — Other Events verify on EDGAR →
• medium

  Enrollment is ongoing in a higher-dose cohort (3x10^12 gc/mL vs 1x10^12 gc/mL), expected to complete mid-2026, with updated trial results planned for first half 2027.

  Exhibit 99.1 verify on EDGAR →